|Bid||15.28 x 0|
|Ask||15.42 x 0|
|Day's Range||15.05 - 15.56|
|52 Week Range||0.81 - 26.25|
|Beta (5Y Monthly)||-0.11|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary Talem Therapeutics LLC ("Talem") has advanced development of a candidate panel of vetted, novel, therapeutic antibodies, collectively referred to as TATX-112, against an undisclosed target, into formal lead candidate characterization.
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced the identification of antibody 23-H7, which preclinical data obtained to date indicates provides strong, protective anti-viral effects in SARS-CoV-2 (COVID-19) infected Syrian hamsters via an uncommon mechanism of action.
Ivanhoé Cambridge is the single-largest investor in Fifth Wall; the first to invest in four Fifth Wall products; and the first investor in Fifth Wall's Climate Tech FundMONTREAL, March 23, 2021 /CNW/ - Ivanhoé Cambridge is proud to announce a strategic partnership with Fifth Wall, the largest venture capital firm with a focus on real estate technology. Ivanhoé Cambridge and Fifth Wall share the belief that their partnership will accelerate Ivanhoé Cambridge's technology adoption and innovation across its portfolio.